By bizn_fun 
Doustdar, who was appointed chief executive last summer, said he hoped the price reduction in Wegovy would be “an investment for our future” and open up access to the drug to more people.
People should expect the company’s share price “goes down before it comes back up,” he told CNBC’s “Early Edition Europe”.
Weight-loss drugs like Novo Nordisk’s Ozempic and Wegovy and Eli Lilly’s Zepbound and Mounjaro have soared in popularity over the last few years, and competition between the firms has driven down prices.
Patent expiry has also led to rise of low-cost copycat weight-loss drugs, with warnings about the safety of some of them.
Novo Nordisk’s chief financial officer Karsten Munk Knudsen told the BBC’s World Business Express that its Indian and Chinese patents on semaglutide – the technical name for the drug used to treat type 2 diabetes and obesity – expire in “a few months’ time”.
He said this would lead to increased competition from similar treatments and expected a “2% impact on group sales for this year”.
Asked about falling prices, he said: “We’re absolutely not in a race to the bottom, but we are in a race to expand the market in a rational way.”